These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37369395)

  • 1. DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A.
    Donners A; van der Zwet K; Egberts ACG; Fijnvandraat K; Mathôt R; Kruis I; Cnossen MH; Schutgens R; Urbanus RT; Fischer K
    BMJ Open; 2023 Jun; 13(6):e072363. PubMed ID: 37369395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab - protocol for a multicentre, open-label, phase IV clinical study.
    Shima M; Takedani H; Kitsukawa K; Taki M; Ishiguro A; Nagao A; Yamaguchi-Suita H; Kyogoku Y; Yoshida S; Nogami K
    BMJ Open; 2022 Jun; 12(6):e059667. PubMed ID: 35697445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.
    Ogiwara K; Taki M; Suzuki T; Takedani H; Matsushita T; Amano K; Matsumoto M; Nishio K; Shima M; Kasahara M; Nogami K
    BMJ Open; 2022 Feb; 12(2):e056922. PubMed ID: 35177463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
    Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
    Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial.
    Takeyama M; Ozu N; Kasama S; Kasahara M; Matsumoto M; Shima M; Nogami K
    BMJ Open; 2023 Jul; 13(7):e072565. PubMed ID: 37429679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.
    Schmitt C; Mancuso ME; Chang T; Podolak-Dawidziak M; Petry C; Sidonio R; Yoneyama K; Key NS; Niggli M; Lehle M; Peyvandi F; Oldenburg J
    Haemophilia; 2023 Jan; 29(1):90-99. PubMed ID: 36271487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.
    Matsushita T; Suzuki N; Nagao A; Nagae C; Yamaguchi-Suita H; Kyogoku Y; Ioka A; Nogami K
    BMJ Open; 2022 Mar; 12(3):e057018. PubMed ID: 35288393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review.
    Donners AAMT; Rademaker CMA; Bevers LAH; Huitema ADR; Schutgens REG; Egberts TCG; Fischer K
    Clin Pharmacokinet; 2021 Nov; 60(11):1395-1406. PubMed ID: 34389928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.
    Tiede A; Hart C; Knöbl P; Greil R; Oldenburg J; Sachs UJ; Miesbach W; Pfrepper C; Trautmann-Grill K; Holstein K; Pilch J; Möhnle P; Schindler C; Weigt C; Schipp D; May M; Dobbelstein C; Pelzer FJ; Werwitzke S; Klamroth R
    Lancet Haematol; 2023 Nov; 10(11):e913-e921. PubMed ID: 37858328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste.
    Donners AAMT; van der Zwet K; Rademaker CMA; Egberts TCG; Schutgens REG; Fischer K
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100074. PubMed ID: 36915864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.
    Samelson-Jones BJ; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Raffini L
    Haemophilia; 2021 Jul; 27(4):591-598. PubMed ID: 34050689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
    Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
    Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.
    Yoneyama K; Schmitt C; Kotani N; Levy GG; Kasai R; Iida S; Shima M; Kawanishi T
    Clin Pharmacokinet; 2018 Sep; 57(9):1123-1134. PubMed ID: 29214439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO).
    Wall C; Xiang H; Palmer B; Chalmers E; Chowdary P; Collins PW; Fletcher S; Hall GW; Hart DP; Mathias M; Sartain P; Shapiro S; Stephensen D; Talks K; Hay CRM;
    Haemophilia; 2023 May; 29(3):743-752. PubMed ID: 36811304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emicizumab for the prevention of bleeds in hemophilia A.
    Mahlangu J
    Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
    [No Abstract]   [Full Text] [Related]  

  • 19. Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.
    Schütte LM; Cnossen MH; van Hest RM; Driessens MHE; Fijnvandraat K; Polinder S; Beckers EAM; Coppens M; Eikenboom J; Laros-van Gorkom BAP; Meijer K; Nieuwenhuizen L; Mauser-Bunschoten EP; Leebeek FWG; Mathôt RAA; Kruip MJHA
    BMJ Open; 2019 Apr; 9(4):e022719. PubMed ID: 31015264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US.
    Lewandowska M; Randall N; Bakeer N; Maahs J; Sagar J; Greist A; Shapiro AD
    Haemophilia; 2021 Jan; 27(1):90-99. PubMed ID: 33245841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.